HS-20089

· Hansoh BioMedical

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for HS-20089, covering 2024-07-18 to 2025-12-17. Get the full timeline:

Most recent: Clinical Trial Update: HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer [Phase 3]